The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00354627|
Recruitment Status : Completed
First Posted : July 20, 2006
Last Update Posted : June 12, 2015
|Condition or disease||Intervention/treatment||Phase|
|HIV-1||Drug: TMC125||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5178 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||February 2012|
|Actual Study Completion Date :||March 2012|
TMC125 200 mg b.i.d. till commercially available.
200 mg b.i.d. till commercially available.
- The primary objective of TMC125-C214 is to provide early access to TMC125 for treatment-experienced HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens and have limited treatment options with currently approved ARVs. [ Time Frame: pregnancy, discontinuation of TMC125 development or when TMC125 has become commercially available in the patient's country. ]
- The secondary objective of this trial is to gather information on the safety and tolerability aspects of TMC125 in combination with other ARVs. Available efficacy data will also be collected. [ Time Frame: pregnancy, discontinuation of TMC125 development or when TMC125 has become commercially available in the patient's country. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00354627
|Study Director:||Tibotec Pharmaceuticals Clinical Trial||Tibotec Pharmaceutical Limited|